Paolo Bossi
YOU?
Author Swipe
View article: Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review
Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review Open
The relative efficacy of cisplatin Q3W versus QW remains under investigation. Cisplatin QW inherently increases the cumulative cisplatin dose more gradually, which may help in managing certain AEs. Treatment guidelines should be updated on…
View article: The Multifaceted Role of Growth Differentiation Factor 15 (GDF15): A Narrative Review from Cancer Cachexia to Target Therapy
The Multifaceted Role of Growth Differentiation Factor 15 (GDF15): A Narrative Review from Cancer Cachexia to Target Therapy Open
Background: Growth Differentiation Factor 15 (GDF15) has emerged as a key biomarker and therapeutic target in oncology, with roles extending beyond cancer cachexia. Elevated GDF15 levels correlate with poor prognosis across several solid t…
View article: The interplay of hypoxia, inflammation, and microbiota as indicators of malignant transformation in oral potentially malignant disorders
The interplay of hypoxia, inflammation, and microbiota as indicators of malignant transformation in oral potentially malignant disorders Open
Oral Potentially Malignant Disorders (OPMDs), such as leukoplakia, erythroplakia, proliferative verrucous leukoplakia, and oral submucous fibrosis, carry a risk of malignant transformation, with reported rates ranging from 2.6 % to 7.9 %. …
View article: Current practices and challenges in the management of cancer-associated thrombosis: a survey of Italian oncologists
Current practices and challenges in the management of cancer-associated thrombosis: a survey of Italian oncologists Open
Purpose This study investigates current practices and challenges in managing cancer-associated thrombosis (CAT) among Italian oncologists, with the objective of evaluating adherence to guidelines for primary thromboprophylaxis, treatment a…
View article: Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Supplementary material
View article: Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Purpose:Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that mona…
View article: Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM) Open
Objective Patient-reported outcomes (PROs) are considered the gold standard for the assessment of subjective symptoms, quality of life (QoL) and patient well-being in both clinical trials and clinical practice. Here, we report key discussi…
View article: INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Purpose: Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that mon…
View article: Improving the multidisciplinary therapeutic management of head and neck squamous cell carcinoma: Consensus statements from an Italian expert panel
Improving the multidisciplinary therapeutic management of head and neck squamous cell carcinoma: Consensus statements from an Italian expert panel Open
These consensus statements provide guidance for optimizing the multidisciplinary management of RM HNSCC, emphasizing personalized treatment strategies, early supportive care, and the importance of clinical trials to address existing uncert…
View article: Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Open
Oral mucositis/stomatitis (hereafter stomatitis) is a common dose-limiting toxicity seen with various classes of cancer treatment. Symptoms associated with stomatitis, primarily oral pain, may impact patient quality of life and may lead to…
View article: Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers
Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers Open
Background Lenvatinib, a multi‐target tyrosine kinase inhibitor (MTKI), has demonstrated activity in recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) in phase II studies. Methods This multicenter, retrospective study included p…
View article: Financial toxicity questionnaire (FIT): development and validation of the italian version (FITALY) in head and neck cancer patients undergoing multimodal curative treatment
Financial toxicity questionnaire (FIT): development and validation of the italian version (FITALY) in head and neck cancer patients undergoing multimodal curative treatment Open
Starting from the Canadian 9-item FIT questionnaire, we developed and validated the Italian 14-item FITALY questionnaire. Prospective application to a cohort of Italian HNC patients is ongoing.
View article: Sinonasal malignancy: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
Sinonasal malignancy: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up Open
•The CPG provides key recommendations and algorithms for managing SMs, excluding mucosal melanoma and soft-tissue sarcomas.•The guideline covers diagnosis, staging, risk assessment, treatment and disease monitoring.•Technological advanceme…
View article: Pain Assessment and Management in Oncological Practice: A Survey from the Italian Network of Supportive Care in Oncology
Pain Assessment and Management in Oncological Practice: A Survey from the Italian Network of Supportive Care in Oncology Open
Background/Objectives: Cancer pain is prevalent across all stages of the disease, significantly impacting patients’ lives. Despite the availability of guidelines, its assessment and management remain suboptimal in many clinical settings. T…
View article: Treatment of OPMD and First Results of Immune Checkpoint Inhibitors
Treatment of OPMD and First Results of Immune Checkpoint Inhibitors Open
Oral potentially malignant diseases (OPMDs) are a group of oral mucosal lesions that have a higher chance of turning into cancer. They show up in different ways, have different causes, and look differently on a microscopic level. To date, …
View article: INCREASING EXPERTISE IN PATIENT-CENTRED BREAKTHROUGH CANCER PAIN MANAGEMENT USING RAPID-ONSET OPIOIDS: FOCUS ON SUBLINGUAL FENTANYL CITRATE
INCREASING EXPERTISE IN PATIENT-CENTRED BREAKTHROUGH CANCER PAIN MANAGEMENT USING RAPID-ONSET OPIOIDS: FOCUS ON SUBLINGUAL FENTANYL CITRATE Open
Cancer pain represents a very frequent symptom in cancer patients; it is one of the factors which most impacts their quality of life, and clinicians often experience issues regarding its management. This study focuses on Breakthrough cance…
View article: Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials Open
Objectives: A combination of chemotherapy and radiotherapy is employed in the curative and postoperative treatment of locally advanced head and neck cancers (HNC). Integrated chemoradiation (CRT) treatments result in a non-negligible rate …
View article: Ectopic olfactory neuroblastoma is associated with increased frequency of syndrome of inappropriate antidiuretic hormone secretion and reduced disease control: Case series with systematic review and pooled analysis
Ectopic olfactory neuroblastoma is associated with increased frequency of syndrome of inappropriate antidiuretic hormone secretion and reduced disease control: Case series with systematic review and pooled analysis Open
Introduction Olfactory neuroblastoma (ONB) is a rare malignant tumor originating from the olfactory neuroepithelium, typically within the sinonasal cavity. Cases of ONB originating outside of the olfactory cleft area are extremely rare and…
View article: Radiomic and Clinical Model in the Prognostic Evaluation of Adenoid Cystic Carcinoma of the Head and Neck
Radiomic and Clinical Model in the Prognostic Evaluation of Adenoid Cystic Carcinoma of the Head and Neck Open
Background/Objectives: Adenoid Cystic Carcinoma (AdCC) is a rare malignant salivary gland tumor, with high rates of recurrence and distant metastasis. This study aims to stratify patients Relapse-Free Survival (RFS) using a combined model …
View article: Diving into hot topics of salivary gland carcinoma management—an EORTC young and early career investigator survey
Diving into hot topics of salivary gland carcinoma management—an EORTC young and early career investigator survey Open
Introduction Recently, the ASCO and ESMO guidelines on salivary gland carcinomas (SGCs) have been released. However, several crucial points lack strong recommendations due to low or intermediate quality of evidence. To better address these…
View article: Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy Open
Recent strides in understanding the molecular underpinnings of head and neck cancers have sparked considerable interest in identifying precise biomarkers that can enhance prognostication and enable personalized treatment strategies. Immuno…
View article: International, Multi-Institutional Evaluation of Practice Patterns and Outcomes for Recurrent and Metastatic Sinonasal Undifferentiated Carcinoma
International, Multi-Institutional Evaluation of Practice Patterns and Outcomes for Recurrent and Metastatic Sinonasal Undifferentiated Carcinoma Open
The aims of this study were to analyze the clinical characteristics of patients with recurrent and metastatic sinonasal undifferentiated carcinoma (SNUC) and evaluate the current treatment strategies to help guide future management. This i…